-
OnCusp Therapeutics’ CUSP06 Receives FDA Fast Track for Ovarian Cancer
•
Sino-US company OnCusp Therapeutics Inc. has announced that it has received Fast Track Designation (FTD) from the US Food and Drug Administration (FDA) for its CUSP06. CUSP06 is a Cadherin-6 targeting antibody-drug conjugate (CDH6 ADC). The targeted indication for this therapy is platinum-resistant ovarian cancer (PROC). Drug DetailsCUSP06, the CDH6…
-
J&J Considers Selling Stroke Care Business Cerenovus for USD1-1.5 Billion
•
US giant Johnson & Johnson (J&J, NYSE: JNJ) is reportedly considering selling its stroke care business Cerenovus. According to the Financial Times, the potential deal could be worth between USD1 billion and USD1.5 billion. Background of CerenovusJ&J established Cerenovus as a neurovascular business unit in 2017. This was done through…
-
Anhui Anke to Invest in Visen Pharma’s Hong Kong IPO as Cornerstone Investor
•
China – based Anhui Anke Biotechnology (Group) Co., Ltd (SHE: 300009) has announced its plan to subscribe to shares of Visen Pharmaceuticals via its initial public offering (IPO) on the Hong Kong Stock Exchange. Anhui Anke will invest up to USD31 million as a cornerstone investor. About Visen PharmaceuticalsVisen Pharmaceuticals…
-
Boao Airport Customs Releases First Batch of Modulen IBD for Crohn’s Disease Management
•
The Boao Airport Customs under Haikou Customs has released the first batch of 96 pieces of Modulen IBD, a nutritionally complete powdered feed. This product is for the dietary management of people with Crohn’s Disease. The release indicates the implementation of a policy. The policy allows designated medical institutions within…
-
AbbVie Collaborates with Xilio Therapeutics on Tumor-Activated Immunotherapies
•
US pharmaceutical giant AbbVie (NYSE: ABBV) has announced a collaboration and option-to-license agreement with fellow US firm Xilio Therapeutics, Inc. (NASDAQ: XLO). The partnership aims to leverage Xilio’s proprietary technology to develop novel tumor-activated, antibody-based immunotherapies, including masked T-cell engagers. Details of the CollaborationXilio, with its proprietary, clinically-validated platform technology…
-
Astellas Pharma’s Izervay Gets FDA Approval for GA Treatment Without Dosing Limit
•
Japan-based Astellas Pharma Inc. (TYO: 4503) has announced that the US Food and Drug Administration (FDA) has approved its label extension application for Izervay (avacincaptad pegol intravitreal solution). The approval allows the drug to treat geographic atrophy (GA) secondary to age-related macular degeneration (AMD) without any limitation on the duration…
-
Andon Health to Fully Control iHealth by Acquiring Best Ventures’ Stake
•
China-based Andon Health Co., Ltd (SHE: 002432) announced a plan to obtain the 20% stake held by Best Ventures, formerly known as Xiaomi Ventures, in iHealth Inc. for USD 46 million. This transaction will make iHealth wholly controlled by Andon Health. Background of iHealthiHealth was a joint venture (JV) between…
-
Hengrui Pharma’s BD Head Dr. Chen Dong Departs for AbbVie’s External Innovation Role
•
Dr. Chen Dong, Vice President and China Head of BD at Jiangsu Hengrui Pharmaceuticals Co., Ltd. (SHA: 600276), has recently departed from the Chinese company. He will now serve as Executive Director of External Innovation at AbbVie. Dr. Chen Dong’s Background and Contributions at HengruiDr. Chen Dong studied at Wuhan…
-
Huadong Medicine’s Biosimilar SaiYueXin Seeks NMPA Approval for Crohn’s Disease
•
Huadong Medicine Co., Ltd (SHE: 000963) announced that another indication approval filing for its SaiYueXin, a biosimilar version of Johnson & Johnson (J&J)’s auto-immune disease drug Stelara (ustekinumab), has been accepted for review by the National Medical Products Administration (NMPA). The Chinese firm is seeking approval for its use in…
-
J&J Innovative Medicine China Appoints New General Manager and Oncology VP
•
Johnson & Johnson (J&J, NYSE: JNJ) Innovative Medicine China has recently made two major appointments to its leadership team. The company has appointed a new general manager and a new vice president. New General ManagerAs of March 1, 2025, Mr. Chen Jian will take on the role of head of…
-
Liaoning Chengda Biotech to See Actual Controller Change of Controlling Shareholder
•
China’s Liaoning Chengda Biotechnology Co., Ltd (SHA: 688739) announced a proposed change in the actual controller of its controlling shareholder Liaoning Chengda Co., Ltd. The actual controller will change from the State-owned Assets Supervision and Administration Commission of Liaoning Provincial Government to no actual controller. Control Change and Its ImplicationsWith…
-
Bayer’s Acoramidis (Beyonttra) Gets EMA Marketing Approval for ATTR-CM Treatment in EU
•
Germany-headquartered Bayer (ETR: BAYN) has received marketing approval from the European Medicines Agency (EMA) for its drug acoramidis, commercially known as Beyonttra. This near-complete (≥90%) transthyretin (TTR) stabilizer can now be used to treat wild-type or variant transthyretin amyloidosis in adult patients with cardiomyopathy (ATTR-CM) in the European Union (EU).…
-
Livzon Pharmaceutical’s JP-1366 Approved for Peptic Ulcer Study by NMPA
•
China-based Livzon Pharmaceutical Group Inc. (HKG: 1513) has obtained approval from the National Medical Products Administration (NMPA) for its JP-1366 injection to conduct clinical studies in the treatment of peptic ulcer bleeding. This is a significant step forward for the company in the field of gastrointestinal therapeutics. About JP-1366JP-1366 is…
-
Pfizer Partners with Alloy Therapeutics to Develop New Antibody Platform
•
US pharmaceutical giant Pfizer (NYSE: PFE) has entered into a multi-year partnership with compatriot firm Alloy Therapeutics Inc. The alliance is designed to develop a new platform aimed at enhancing Pfizer’s ability to discover potent, specific, and effective antibodies against targets that are difficult to address with existing antibody discovery…
-
Lifetech Scientific’s Aortic Stent Graft System Wins NMPA Approval
•
China-based Lifetech Scientific Corporation (HKG: 1302) announced that it has received market approval from the National Medical Products Administration (NMPA) for its aortic stent graft system, co-developed by Fuwai Hospital. Product OverviewThe aortic stent graft system is the first of its kind in China specifically designed for chimney technology. It…
-
Eli Lilly Expands Collaboration with AdvanCell on Targeted Alpha Therapies for Cancer
•
Eli Lilly & Co. (NYSE: LLY) has expanded its collaboration with Australia-based AdvanCell, a clinical-stage radiopharmaceutical company, to develop targeted alpha therapies for various cancers. The partnership will leverage AdvanCell’s Pb-212 production technology and Lilly’s drug development expertise. Collaboration DetailsThe agreement combines AdvanCell’s proprietary radionuclide infrastructure with Lilly’s drug candidate…
-
Eli Lilly Licenses OliX Pharma’s OLX75016 for MASH and Cardiometabolic Diseases
•
Eli Lilly & Co. (NYSE: LLY) has signed a licensing agreement with OliX Pharmaceuticals, Inc. (KOSDAQ: 226950), a South Korea-based RNAi therapeutics developer, to jointly develop and commercialize OLX75016, an investigational drug targeting metabolic-associated steatohepatitis (MASH) and other cardiometabolic indications. Drug ProfileOLX75016, derived from a genome-wide association study (GWAS), is…
-
Gilead Sciences’ Q4 2024 Financials Show 6% Revenue Growth, Driven by HIV and Oncology
•
Gilead Sciences Inc. (NASDAQ: GILD) reported a 6% year-on-year (YOY) increase in global revenues for Q4 2024, reaching USD 7.6 billion, driven by strong performance in HIV, oncology, and liver disease segments. Full-year revenues also rose 6% to USD 28.8 billion. Product Performance Geographical Breakdown Outlook for 2025Gilead plans to…
-
Lion TCR’s Liocyx-M00 Therapy Receives FDA Clearance for HBV-Related HCC Study
•
Singapore-based clinical-stage biotechnology company Lion TCR, backed by Chinese investors, has received clearance from the US Food and Drug Administration (FDA) to initiate a global, multi-center Phase II study for its Liocyx-M00 therapy. The treatment involves autologous T-cells transfected with mRNA encoding hepatitis B surface antigen (HBsAg) specific toll cell…
-
Hainan Poly Pharm’s Generic ProHance Wins FDA Approval in US
•
China-based Hainan Poly Pharm Co., Ltd (SHE: 300630) announced that the US Food and Drug Administration (FDA) has approved its generic version of Bracco’s ProHance (gadoteridol), making it the first and currently only ProHance generic available in the US. The approved strengths include 1.3965 g/5 mL, 2.793 g/10 mL, 4.1895…
